AC
MTCR

Apogem Capital’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Apogem Capital’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-88,656
Closed -$304K – 217
2021
Q3 		$304K Buy
88,656
+21,334
+32% +$66.5K 0.19% 148
2021
Q2 		$256K Buy
67,322
+43,883
+187% +$181K 0.16% 155
2021
Q1 		$145K Sell
23,439
-11,711
-33% -$104K 0.1% 164
2020
Q4 		$276K Buy
+35,150
New +$322K 0.18% 135

Other funds holding MTCR

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Apogem Capital's MTCR Position: Q4 2021 in Review

Apogem Capital sold out of Metacrine, Inc. Common Stock (MTCR) in Q4 2021, closing a stake of 88,656 shares — an estimated $304K sold.

Apogem Capital first reported a position in MTCR in Q4 2020 and held it in 4 quarters. The position peaked at $304K in Q3 2021. 31 funds tracked by Wall St. Rank hold MTCR as of Q4 2021.

  • Apogem Capital reported no remaining Metacrine, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Apogem Capital sold 88,656 Metacrine, Inc. Common Stock shares in Q4 2021, an estimated $304K.
  • Apogem Capital first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Apogem Capital's Metacrine, Inc. Common Stock position peaked at $304K in Q3 2021.
  • 31 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q4 2021.

Based on Apogem Capital's 13F filing for Q4 2021, filed 14 Feb 2022.